Oligonucleotide conjugates for therapeutic applications

Therapeutic Delivery

Volumn 4, Issue 7, 2013, Pages 791-809

  Winkler, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 745; ALICAFORSEN; API 1002; ARC 520; BEVASIRANIB; CARBOHYDRATE; CHOLESTEROL; CUSTIRSEN; DRISAPERSEN; ETEPLIRSEN; FOLIC ACID; GTI 2040; IMETELSTAT; ISIS 481464; MIPOMERSEN; MIRAVIRSEN; OLIGONUCLEOTIDE; PEPTIDE APTAMER; PROTEIN DERIVATIVE; RXI109; SYL 040012; TOCOPHEROL; UNCLASSIFIED DRUG;

DRUG CONJUGATION; DRUG FORMULATION; DRUG TARGETING; DRUG UPTAKE; DUCHENNE MUSCULAR DYSTROPHY; FAMILIAL HYPERCHOLESTEROLEMIA; HEPATITIS B; HEPATITIS C; LIGAND BINDING; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SOLID PHASE SYNTHESIS; ULCERATIVE COLITIS;

EID: 84880915038     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.47     Document Type: Review

References (127)

1. Bennett CF, Swayze EE. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010
2. Burnett JC, Rossi JJ. RNA-based therapeutics: Current progress and future prospects. Chem. Biol. 19(1), 60-71 (2012
3. Yamamoto T, Nakatani M, Narukawa K, Obika S. Antisense drug discovery and development. Future Med. Chem. 3(3), 339-365 (2011
4. Opar A. Exon-skipping drug pulls ahead in muscular dystrophy field. Nat. Med. 18(9), 1314 (2012
5. Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19(1), 1-13 (2009
6. Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm. Res. 28(12), 2983-2995 (2011
7. Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm. Res. 28(12), 3043-3049 (2011
8. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9(7), 537-550 (2010
9. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int. J. Nanomed. 7, 2181-2195 (2012
10. Dirin M, Winkler J. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther. 13(6), 875-888 (2013
11. Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39(11), 4795-4807 (2011
12. Stessl M, Noe CR, Winkler J. Off-Target effects and safety aspects of phosphorothioate oligonucleotides. In: From Nucleic Acids Sequences to Molecular Medicine, RNA Technologies. Erdmann VA, Barciszewski J (Eds). Springer Verlag, Berlin, Germany, 67-83 (2012
13. Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: Paradigms and challenges. Acc. Chem. Res. 45(7), 1163-1171 (2012
14. McGowan MP, Tardif J-C, Ceska R et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7(11), e49006 (2012
15. Gelsinger C, Steinhagen-Thiessen E, Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs 72(11), 1445-1455 (2012
16. Parhofer KG. Mipomersen: Evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid. 7, 29-38 (2012
17. Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33(9), 1142-1149 (2012
18. Bedikian AY, Lebbé; C, Robert C et al. Survival in a Phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). J. Clin. Oncol. 29(15 Suppl.), 8531 (2011
19. Goemans NM, Tulinius M, van den Akker JT et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364(16), 1513-1522 (2011
20. Cirak S, Arechavala-Gomeza V, Guglieri M et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, Phase 2, dose-escalation study. Lancet 378(9791), 595-605 (2011
21. Cirak S, Feng L, Anthony K et al. Restoration of the dystrophin- Associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol. Ther. 20(2), 462-467 (2012
22. Noe CR, Winkler J, Urban E, Gilbert M, Haberhauer G, Brunar H. Zwitterionic oligonucleotides: A study on binding properties of 2́;-O-Aminohexyl modifications. Nucleosides Nucleotides Nucleic Acids 24(8), 1167-1185. (2005
23. Winkler J, Urban E, Noe CR. Oligonucleotides conjugated to short lysine chains. Bioconjug. Chem. 16(4), 1038-1044. (2005
24. Winkler J, Gilbert M, Kocourková; A, Stessl M, Noe CR. 2́;-O-Lysylaminohexyl oligonucleotides: Modifications for antisense and siRNA. ChemMedChem 3(1), 102-110 (2008
25. Stein CA, Hansen JB, Lai J et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38(1), e3 (2010
26. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010
27. Jayaraman M, Ansell SM, Mui BL et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51(34), 8529-8533 (2011
28. Zhou J, Shum K-T, Burnett J, Rossi J. Nanoparticle-based delivery of RNAi therapeutics: Progress and challenges. Pharmaceuticals 6(1), 85-107 (2013
29. Wagner E. Polymers for siRNA delivery: Inspired by viruses to be targeted, dynamic, and precise. Acc. Chem. Res. 45(7), 1005-1013 (2011
30. Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther. Deliv. 2(7), 891-905 (2011
31. Straarup EM, Fisker N, Hedtjärn M et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38(20), 7100-7111 (2010
32. Lindow M, Kauppinen S. Discovering the first microRNA-Targeted drug. J. Cell Biol. 199(3), 407-412 (2012
33. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques 44(5), 619-626 (2008
34. Amann R, Fuchs BM. Single-cell identification in microbial communities by improved fluorescence in situ hybridization techniques. Nat. Rev. Microbiol. 6(5), 339-348 (2008
35. Juliano RL, Ming X, Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc. Chem. Res. 45(7), 1067-1076 (2012
36. Juliano RL, Ming X, Nakagawa O. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug. Chem. 23(2), 147-157 (2012
37. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173-178 (2004
38. Wolfrum C, Shi S, Jayaprakash KN et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25(10), 1149-1157 (2007
39. Wong SC, Klein JJ, Hamilton HL et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acids Therap. 22(6), 380-390 (2012
40. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006
41. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26(5), 561-569 (2008
42. Herbert B-S, Gellert GC, Hochreiter A et al. Lipid modification of GRN163, an N3́;→P5́; thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24(33), 5262-5268 (2005
43. Gryaznov SM. Oligonucleotide N3́;→P5́; phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem. Biodivers. 7(3), 477-493 (2010
44. Nishina K, Unno T, Uno Y et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-Tocopherol. Mol. Ther. 16(4), 734-740 (2008
45. Uno Y, Piao W, Miyata K, Nishina K, Mizusawa H, Yokota T. High-density lipoprotein facilitates in vivo delivery of a-Tocopherol-conjugated short-interfering RNA to the brain. Hum. Gene Ther. 22(6), 711-719 (2010
46. Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67(5), 715-726 (2010
47. van den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22(6), 888-893 (2011
48. Eguchi A, Dowdy SF. siRNA delivery using peptide transduction domains. Trends Pharmacol. Sci. 30(7), 341-345 (2009
49. Gump JM, June RK, Dowdy SF. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J. Biol. Chem. 285(2), 1500-1507 (2010
50. Lindberg S, Copolovici DM, Langel Ü. Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther. Deliv. 2(1), 71-82 (2011
51. Ivanova GD, Arzumanov A, Abes R et al. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36(20), 6418-6428 (2008
52. Abes R, Arzumanov AA, Moulton HM et al. Cell-penetrating-peptide-based delivery of oligonucleotides: An overview. Biochem. Soc. Trans. 35(Pt 4), 775-779 (2007
53. Moulton JD, Jiang S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 14(3), 1304-1323 (2009
54. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 1798(12), 2296-2303 (2010
55. Yin H, Moulton HM, Seow Y et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17(24), 3909-3918 (2008
56. Yin H, Moulton HM, Betts C et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 18(22), 4405-4414 (2009
57. Swenson DL, Warfield KL, Warren TK et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 53(5), 2089-2099 (2009
58. Pons B, Kotera M, Zuber G, Behr J-P. Online synthesis of diblock cationic oligonucleotides for enhanced hybridization to their complementary sequence. ChemBioChem 7(8), 1173-1176 (2006
59. Noir R, Kotera M, Pons B, Remy JS, Behr JP. Oligonucleotide-oligospermine conjugates (zip nucleic acids): A convenient means of finely tuning hybridization temperatures. J. Am. Chem. Soc. 130(40), 13500-13505 (2008
60. Winkler J, Saadat K, Dí;az Gavilá;n M, Urban E, Noe CR. Oligonucleotide polyamine conjugates: Influence of length and position of 2́;-Attached polyamines on duplex stability and antisense effect. Eur. J. Med. Chem. 44(2), 670-677 (2009
61. Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123-132 (2006
62. Rosina C, Bottoni F, Staurenghi G. Clinical experience with pegaptanib sodium. Clin. Ophthalmol. 2(3), 485-488 (2008
63. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-Angiogenic gene therapy. J. Control. Release 116(2), 123-129 (2006
64. Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr. Opin. Chem. Biol. 14(4), 520-528 (2010
65. Cuesta Á;.M, Sainz-Pastor N, Bonet J, Oliva B, Á;lvarez-Vallina L. Multivalent antibodies: When design surpasses evolution. Trends Biotechnol. 28(7), 355-362 (2010
66. Boersma YL, Plückthun A. DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr. Opin. Biotechnol. 22(6), 849-857 (2011
67. Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23(6), 709-717 (2005
68. Yao YD, Sun TM, Huang SY et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl Med. 4(130), 130-148 (2012
69. Winkler J, Martin-Killias P, Pluckthun A, Zangemeister-Wittke U. EpCAM-Targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 8(9), 2674-2683 (2009
70. Xia C-F, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol. Pharm. 6(3), 747-751 (2008
71. Manjappa AS, Chaudhari KR, Venkataraju MP et al. Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J. Control. Release 150(1), 2-22 (2011
72. Sawant R, Torchilin V. Challenges in development of targeted liposomal therapeutics. AAPS J. 14(2), 303-315 (2012
73. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich D. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug. Chem. 18(3), 983-988 (2007
74. Liu Y, Cheng D, Liu X et al. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation. Nucl. Med. Biol. 39(1), 101-107 (2012
75. Ikeda Y, Taira K. Ligand-Targeted delivery of therapeutic siRNA. Pharm. Res. 23(8), 1631-1640 (2006
76. Yu B, Zhao X, Lee LJ, Lee R. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11(1), 195-203 (2009
77. Wurch T, Pierré; A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: From discovery to clinical proof-of-concept. Trends Biotechnol. 30(11), 575-582 (2012
78. Tamaskovic R, Simon M, Stefan N, Schwill M, Plückthun A. Designed ankyrin repeat proteins (DARPins): From research to therapy. In: Methods Enzymol. Wittrup KD, Gregory LV (Eds). Academic Press, MA, USA, 101-134 (2012
79. Simon M, Zangemeister-Wittke U, Plückthun A. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjug. Chem. 23(2), 279-286 (2012
80. Uckun FM, Qazi S, Dibirdik I, Myers DE. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. Integr. Biol. 5(1), 122-132 (2013
81. Dohmen C, Frohlich T, Lachelt U et al. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol. Ther. Nucleic Acids 1, e7 (2012
82. Nakagawa O, Ming X, Huang L, Juliano RL. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J. Am. Chem. Soc. 132(26), 8848-8849 (2010
83. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-Acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41(1), 120-129 (2007
84. Thomas M, Kularatne SA, Qi L et al. Ligand-Targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32-39 (2009
85. Khorev O, Stokmaier D, Schwardt O, Cutting B, Ernst B. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg. Med. Chem. 16(9), 5216-5231 (2008
86. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18(7), 1357-1364 (2010
87. Wakefield DH, Klein JJ, Wolff JA, Rozema DB. Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size. Bioconjug. Chem. 16(5), 1204-1208 (2005
88. Rozema DB, Lewis DL, Wakefield DH et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104(32), 12982-12987 (2007
89. Wooddell CI, Rozema DB, Hossbach M et al. Hepatocyte-Targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21(5), 973-985 (2013
90. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16(5), 942-946 (2008
91. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug. Chem. 20(10), 1908-1916 (2009
92. Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ. Cell adhesion molecules for targeted drug delivery. J. Pharm. Sci. 95(9), 1856-1872 (2006
93. Alam MR, Dixit V, Kang H et al. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res. 36(8), 2764-2776 (2008
94. Alam MR, Ming X, Fisher M et al. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug. Chem. 22(8), 1673-1681 (2011
95. Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: A critical review. Life Sci. 77(14), 1584-1604 (2005
96. Willibald J, Harder J, Sparrer K, Conzelmann K-K, Carell T. Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells. J. Am. Chem. Soc. 134(30), 12330-12333 (2012
97. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug. Chem. 18(6), 1831-1840 (2007
98. Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 38(19), 6567-6576 (2010
99. Mayer G. The chemical biology of aptamers. Angew. Chem. Int. Ed. Engl. 48(15), 2672-2689 (2009
100. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W. Development of DNA aptamers using Cell-SELEX. Nat. Protocols 5(6), 1169-1185 (2010
101. McNamara JO, Andrechek ER, Wang Y et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24(8), 1005-1015 (2006
102. Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27(9), 839-849 (2009
103. Zhou J, Rossi J. Aptamer-Targeted cell-specific RNA interference. Silence 1(1), 4 (2010
104. Lonnberg H. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. Bioconjug. Chem. 20(6), 1065-1094 (2009
105. Rao M, Sockanathan S. Molecular mechanisms of RNAi: Implications for development and disease. Birth Defects Res. C Embryo Today 75(1), 28-42. (2005
106. Lu K, Duan Q-P, Ma L, Zhao D-X. Chemical strategies for the synthesis of peptide-oligonucleotide conjugates. Bioconjug. Chem. 21(2), 187-202 (2009
107. Winkler J, Urban E, Losert D, Wacheck V, Pehamberger H, Noe CR. A novel concept for ligand attachment to oligonucleotides via a 2́;-succinyl linker. Nucleic Acids Res. 32(2), 710-718 (2004
108. Winkler J, Giessrigl B, Novak C, Urban E, Noe CR. 2́;-O- lysylaminohexyladenosine modified oligonucleotides. Monatsh. Chem. 141(7), 809-815 (2010
109. Singh Y, Murat P, Defrancq E. Recent developments in oligonucleotide conjugation. Chem. Soc. Rev. 39(6), 2054-2070 (2010
110. Saito G, Swanson JA, Lee K-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55(2), 199-215 (2003
111. El-Sagheer AH, Brown T. Click chemistry with DNA. Chem. Soc. Rev. 39(4), 1388-1405 (2010
112. Dieterich DC, Hodas JJL, Gouzer G et al. In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons. Nat. Neurosci. 13(7), 897-905 (2010
113. Jeffery DA, Bogyo M. Chemical proteomics and its application to drug discovery. Curr. Opin. Biotechnol. 14(1), 87-95 (2003
114. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2(3), 214-221 (2003
115. Kumari S, Mg S, Mayor S. Endocytosis unplugged: Multiple ways to enter the cell. Cell Res. 20(3), 256-275 (2010
116. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857-902 (2009
117. Sandvig K, Pust S, Skotland T, van Deurs B. Clathrin-independent endocytosis: Mechanisms and function. Curr. Opin. Cell Biol. 23(4), 413-420 (2011
118. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 8(8), 603-612 (2007
119. Hanss B, Leal-Pinto E, Bruggeman LA, Copeland TD, Klotman PE. Identification and characterization of a cell membrane nucleic acid channel. Proc. Natl Acad. Sci USA 95(4), 1921-1926 (1998
120. Alam MR, Ming X, Dixit V, Fisher M, Chen X, Juliano RL. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides 20(2), 103-109 (2010
121. Geary RS, Wancewicz E, Matson J et al. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2́;-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem. Pharmacol. 78(3), 284-291 (2009
122. Sigismund S, Woelk T, Puri C et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl Acad. Sci. USA 102(8), 2760-2765 (2005
123. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J. Control. Release 151(3), 220-228 (2011
124. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7(5), 657-663 (2005
125. Dominska M, Dykxhoorn DM. Breaking down the barriers: SiRNA delivery and endosome escape. J. Cell Sci. 123(8), 1183-1189 (2010
126. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl Acad. Sci. USA 103(5), 1522-1527 (2006
127. Winkler J, Stessl M, Amartey J, Noe CR. Off-Target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem 5(8), 1344-1352 (2010